ProteKt Therapeutics, based in Ness Ziona, Israel, develops potent and selective oral inhibitors of the kinase PKR for treatment of neurodegenerative and neuroinflammatory diseases. The company discovers molecules using unique computational methods and validates inhibitors in clinically relevant assays. ProteKt plans to select a lead drug candidate and validate its neurotherapeutic effects in vivo. It also intends to initiate clinical development of a related diagnostic assay for patient selection and treatment personalization. The company raised $3.6M in equity financing to support these development and validation activities. Led by CEO Yotam Nisemblat, ProteKt was founded by Carmel, Haifa University Economic Corporation and the Carmel Innovations Fund based on the research of Prof. Kobi Rosenblum and joined the FutuRx accelerator in 2015.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2019